Kindred Biosciences, Inc. (KIN): Price and Financial Metrics


Kindred Biosciences, Inc. (KIN): $4.63

0.04 (+0.87%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add KIN to Watchlist
Sign Up

Industry: Biotech


Ranked

of 318

in industry

KIN Stock Summary

  • With a market capitalization of $181,070,052, Kindred Biosciences Inc has a greater market value than just 23.18% of US stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 1.4 for Kindred Biosciences Inc; that's greater than it is for only 20.05% of US stocks.
  • As for revenue growth, note that KIN's revenue has grown 919.23% over the past 12 months; that beats the revenue growth of 98.99% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Kindred Biosciences Inc are CERS, VXRT, EPZM, GTHX, and TRVN.
  • KIN's SEC filings can be seen here. And to visit Kindred Biosciences Inc's official web site, go to www.kindredbio.com.

KIN Stock Price Chart Interactive Chart >

Price chart for KIN

KIN Price/Volume Stats

Current price $4.63 52-week high $11.93
Prev. close $4.59 52-week low $3.11
Day low $4.45 Volume 100,906
Day high $4.68 Avg. volume 477,586
50-day MA $4.76 Dividend yield N/A
200-day MA $4.35 Market Cap 182.85M

Kindred Biosciences, Inc. (KIN) Company Bio


Kindred Biosciences, Inc., a development stage biopharmaceutical company, focuses on the development of therapies for pets. The company’s product pipeline consists of small molecules and biologics for a range of indications in dogs, cats, and horses. The company was founded in 2012 and is based in Burlingame, California.


KIN Latest News Stream


Event/Time News Detail
Loading, please wait...

KIN Latest Social Stream


Loading social stream, please wait...

View Full KIN Social Stream

Latest KIN News From Around the Web

Below are the latest news stories about Kindred Biosciences Inc that investors may wish to consider to help them evaluate KIN as an investment opportunity.

Kindred Biosciences Announces Two New Appointments to Board of Directors

Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has appointed Lyndon Lien, Ph.D., an experienced biotech CEO, entrepreneur and investor, and Nanxi Liu, CEO and Co-Founder of Enplug and Co-Founder of Nanoly Bioscience, to its Board of Directors, effective February 5, 2021.

Yahoo | February 9, 2021

EFFECT - Kindred Biosciences, Inc. (0001561743) (Filer) - Stocks News Feed

Accepted 2021-02-03 00:15:50 Documents Thank you for supporting Stocks News Feed. As an Amazon affiliate, we earn from qualifying purchases. 1 Effectiveness Date 2021-02-02 Registration Form S-3 Document Format Files Mailing Address 1555 BAYSHORE HIGHWAY, SUITE 200 BURLINGAME CA 94010 Business Address 1555 BAYSHORE HIGHWAY, SUITE 200 BURLINGAME CA 94010 650-701-7901 Kindred Biosciences, Inc. (Filer)… Read More »EFFECT – Kindred Biosciences, Inc. (0001561743) (Filer)

Stocks News Feed | February 2, 2021

These 2 Penny Stocks Could Rally All the Way to $11, Say Analysts

At its January FOMC meeting, the Federal Reserve held interest rates steady – they are near rock-bottom now, and to no one’s surprise, the Fed is keeping them there. Fed Chairman Jerome Powell may have fed some market pessimism when he spoke after the meeting, and pointed out that unemployment, which has been rising in recent months. For market watchers seeking support, there is solace in the Fed’s monetary policy. The central bank is committed to buying $80 billion monthly in Treasury notes, and has put a rate increase on hold, likely until 2023. At least one top strategist sees the current market environment in terms of opportunity.

Michael Marcus on TipRanks | January 28, 2021

Kindred Biosciences, Inc. (NASDAQ:KIN) Director Sells $195,345.00 in Stock

Kindred Biosciences, Inc. (NASDAQ:KIN) Director Denise Bevers sold 39,069 shares of the firm’s stock in a transaction dated Thursday, January 7th. The stock was sold at an average price of $5.00, for a total value of $195,345.00. Following the transaction, the director now owns 143,835 shares in the company, valued at approximately $719,175. The sale […]

Watchlist News | January 9, 2021

Kindred Biosciences Announces Positive Results from Pilot Field Effectiveness Study for Anti-TNFα Antibody for Canine Inflammatory Bowel Disease

Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced positive results from the pilot field effectiveness study of its monoclonal antibody against tumour necrosis factor alpha (anti-TNFα antibody) for canine inflammatory bowel disease (IBD).

Yahoo | December 21, 2020

Read More 'KIN' Stories Here

KIN Price Returns

1-mo 0.87%
3-mo 18.72%
6-mo 10.50%
1-year -52.07%
3-year -45.85%
5-year 20.57%
YTD 7.42%
2020 -49.17%
2019 -22.56%
2018 15.87%
2017 122.35%
2016 25.00%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.8857 seconds.